Basic Analysis of the Cerebrospinal Fluid: An Important Framework for Laboratory Diagnostics of the Impairment of the Central Nervous System.
aspartate aminotransferase
blood-brain barrier
blood-cerebrospinal fluid barrier
cerebrospinal fluid
coefficient of energy balance
cytological-energy analysis
Journal
Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761
Informations de publication
Date de publication:
14 Aug 2022
14 Aug 2022
Historique:
received:
27
04
2022
revised:
02
08
2022
accepted:
11
08
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
26
8
2022
Statut:
epublish
Résumé
Laboratory analysis of basic cerebrospinal fluid (CSF) parameters is considered as essential for any CSF evaluation. It can provide rapidly very valuable information about the status of the central nervous system (CNS). Our retrospective study evaluated parameters of basic CSF analysis in cases of either infectious or non-infectious CNS involvement. Neutrophils are effector cells of innate immunity. Predominance of neutrophils was found in 98.2% of patients with purulent inflammation in CNS. Lymphocytes are cellular substrate of adaptive immunity. We found their predominance in 94.8% of patients with multiple sclerosis (MS), 66.7% of patients with tick-borne encephalitis (TBE), 92.2% of patients with neuroborreliosis, 83.3% of patients with inflammatory response with oxidative burst of macrophages in CNS and 75.0% of patients with malignant infiltration of meninges (MIM). The simultaneous assessment of aerobic and anaerobic metabolism in CSF using the coefficient of energy balance (KEB) allows us to specify the type of inflammation in CNS. We found predominantly aerobic metabolism (KEB > 28.0) in 100.0% CSF of patients with normal CSF findings and in 92.8% CSF of patients with MS. Predominant faintly anaerobic metabolism (28.0 > KEB > 20.0) in CSF was found in 71.8% patients with TBE and in 64.7% patients with neuroborreliosis. Strong anaerobic metabolism (KEB < 10.0) was found in the CSF of 99.1% patients with purulent inflammation, 100.0% patients with inflammatory response with oxidative burst of macrophages and in 80.6% patients with MIM. Joint evaluation of basic CSF parameters provides sufficient information about the immune response in the CSF compartment for rapid and reliable diagnosis of CNS involvement.
Identifiants
pubmed: 36005147
pii: cimb44080251
doi: 10.3390/cimb44080251
pmc: PMC9406567
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3666-3680Subventions
Organisme : The Internal Grant of the Krajská zdravotní, a.s. in Ústí nad Labem, Czech Republic
ID : IGA-KZ-2021-1-2
Organisme : Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic, Cooperatio Program, research area IMMU.
Références
J Neurol. 1998 May;245(5):262-72
pubmed: 9617706
Intern Emerg Med. 2021 Jun;16(4):1031-1042
pubmed: 33420904
Immunol Lett. 2017 Dec;192:88-96
pubmed: 28864335
Clin Exp Immunol. 2005 Apr;140(1):73-80
pubmed: 15762877
J Clin Invest. 1982 Sep;70(3):550-7
pubmed: 7107894
J Neurol. 2012 Apr;259(4):630-6
pubmed: 21898139
Adv Clin Chem. 2001;36:1-62
pubmed: 11605255
Neurology. 2010 Feb 2;74(5):399-405
pubmed: 20124205
J Clin Microbiol. 2011 May;49(5):2027-30
pubmed: 21367992
Handb Clin Neurol. 2014;122:681-702
pubmed: 24507540
J Biol Chem. 1986 Sep 25;261(27):12616-23
pubmed: 3017982
Indian J Med Res. 2019 Aug;150(2):117-130
pubmed: 31670267
Brain Sci. 2020 Oct 01;10(10):
pubmed: 33019758
Clin Chem Lab Med. 2014 Jul;52(7):1009-17
pubmed: 24622789
Clin Infect Dis. 1999 Apr;28(4):882-90
pubmed: 10825054
Exp Neurol. 2015 May;267:78-86
pubmed: 25747036
Vaccine. 2003 Apr 1;21 Suppl 1:S36-40
pubmed: 12628812
Fluids Barriers CNS. 2016 Oct 31;13(1):19
pubmed: 27799072
J Bras Nefrol. 2020 Jul-Sep;42(3):375-379
pubmed: 32406475
J Clin Immunol. 2001 Mar;21(2):81-92
pubmed: 11332657
Neurology. 1995 Sep;45(9):1663-70
pubmed: 7675224
Brain Res Brain Res Rev. 2001 Oct;36(2-3):258-64
pubmed: 11690623
Lancet. 2008 May 31;371(9627):1861-71
pubmed: 18514730
Infect Dis Clin North Am. 2008 Sep;22(3):561-75, x
pubmed: 18755391
Neurol India. 2021 Nov-Dec;69(Supplement):S443-S455
pubmed: 35103001
J Infect. 2018 Dec;77(6):509-515
pubmed: 30217659
Dis Markers. 2013;35(6):687-99
pubmed: 24324285
Cancer. 2018 Jan 1;124(1):21-35
pubmed: 29165794
Life (Basel). 2021 Apr 01;11(4):
pubmed: 33915782
Mult Scler. 2020 Apr;26(5):582-590
pubmed: 31965889
Fluids Barriers CNS. 2020 May 6;17(1):35
pubmed: 32375819
Malays J Pathol. 2015 Apr;37(1):1-9
pubmed: 25890607
Life (Basel). 2022 Jan 21;12(2):
pubmed: 35207447
Clin Rheumatol. 2018 Jan;37(1):271-275
pubmed: 28785856
Clin Chem Lab Med. 2022 Feb 25;60(6):e129-e131
pubmed: 35218632
J Immunol Res. 2017;2017:9671604
pubmed: 28299345
Biomed Res Int. 2013;2013:745943
pubmed: 23865063
Br Med Bull. 2005 Apr 18;72:99-118
pubmed: 15838017
J Leukoc Biol. 2013 Feb;93(2):185-98
pubmed: 23066164
BMC Infect Dis. 2020 Nov 16;20(1):844
pubmed: 33198666
Annu Rev Immunol. 2005;23:197-223
pubmed: 15771570
J Neuroinflammation. 2016 Oct 18;13(1):273
pubmed: 27756335
Am Fam Physician. 2003 Sep 15;68(6):1103-8
pubmed: 14524396
Ann Neurol. 1995 Jun;37(6):691-702
pubmed: 7778842
Nat Rev Immunol. 2016 Sep;16(9):553-65
pubmed: 27396447
Infect Immun. 2001 Aug;69(8):4980-7
pubmed: 11447176
Crit Rev Clin Lab Sci. 2020 Mar;57(2):86-98
pubmed: 31694431
Physiol Rev. 2013 Oct;93(4):1847-92
pubmed: 24137023
Eur Arch Otorhinolaryngol. 2016 Sep;273(9):2481-6
pubmed: 26645106
Chin Clin Oncol. 2015 Jun;4(2):26
pubmed: 26112812
J Neurol. 1998 May;245(5):247-55
pubmed: 9617704
Nat Rev Neurol. 2015 Aug;11(8):446-56
pubmed: 26215621
N Engl J Med. 2000 Sep 28;343(13):938-52
pubmed: 11006371
J Immunol Methods. 1999 Dec 17;232(1-2):3-14
pubmed: 10618505
Oncologist. 2008 Sep;13(9):967-77
pubmed: 18776058
Immunol Rev. 1997 Aug;158:57-67
pubmed: 9314074
World J Clin Cases. 2015 May 16;3(5):430-41
pubmed: 25984517
Transl Stroke Res. 2011 Dec;2(4):492-516
pubmed: 22299022